Alnylam Pharma (DUL) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DUL Analyst Ratings

Strong Buy

16 Buy

3 Hold

0 Sell

Based on 19 analysts giving stock ratings to

Alnylam

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DUL Stock 12 Month Forecast

Average Price Target

CHF301.37

▲(21.38% Upside)

Based on 19 Wall Street analysts offering 12 month price targets for Alnylam Pharma in the last 3 months. The average price target is CHF301.37 with a high forecast of CHF444.78 and a low forecast of CHF186.00. The average price target represents a 21.38% change from the last price of CHF248.28.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"165":"CHF165","235":"CHF235","305":"CHF305","375":"CHF375","445":"CHF445"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":444.779423,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF444.78</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":301.37175449333336,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF301.37</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":185.9986678,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF186.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[165,235,305,375,445],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,166.559,187.960571,209.362142,230.763713,252.16528399999999,273.566855,294.968426,316.369997,337.771568,359.173139,380.57471,401.976281,423.37785199999996,{"y":444.779423,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,166.559,176.92921188410256,187.29942376820514,197.6696356523077,208.03984753641026,218.41005942051282,228.78027130461538,239.15048318871797,249.52069507282053,259.8909069569231,270.2611188410257,280.63133072512824,291.0015426092308,{"y":301.37175449333336,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,166.559,168.05435906153846,169.54971812307693,171.0450771846154,172.54043624615383,174.0357953076923,175.53115436923076,177.02651343076923,178.5218724923077,180.01723155384616,181.5125906153846,183.00794967692306,184.50330873846153,{"y":185.9986678,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":228.981,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":228.981,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":228.981,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":228.981,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":228.981,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":228.981,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":228.981,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":228.981,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":228.981,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":228.981,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":228.981,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":248.279,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":166.559,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetCHF444.78

Average Price TargetCHF301.37

Lowest Price TargetCHF186.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Cory Kasimov

Evercore ISI

CHF323.48→CHF262.82

Buy

5.86%

Upside

Reiterated

08/05/26

Alnylam price target lowered to $325 from $400 at Evercore ISIAlnylam price target lowered to $325 from $400 at Evercore ISI

Patrick Trucchio

H.C. Wainwright

CHF392.21→CHF367.95

Buy

48.20%

Upside

Reiterated

08/04/26

H.C. Wainwright Sticks to Its Buy Rating for Alnylam Pharma (ALNY)

Danielle Brill

Truist Financial

CHF331.56→CHF254.74

Buy

2.60%

Upside

Assigned

08/04/26

Truist Financial Releases a Buy Rating on Alnylam Pharma (ALNY)

Jessica Fye

J.P. Morgan

CHF303.26

Buy

22.14%

Upside

Reiterated

08/04/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (NASDAQ: ARWR), OnKure Therapeutics (NASDAQ: OKUR) and Alnylam Pharma (NASDAQ: ALNY)

Whitney Ijem

Canaccord Genuity

CHF346.93

Buy

39.73%

Upside

Reiterated

08/03/26

Canaccord Genuity Sticks to Their Buy Rating for Alnylam Pharma (ALNY)

Eric Joseph

Citi

CHF307.3→CHF274.95

Buy

10.74%

Upside

Reiterated

08/03/26

Alnylam price target lowered to $340 from $380 at CitiAlnylam price target lowered to $340 from $380 at Citi

Eliana Merle

Barclays

CHF426.18→CHF363.91

Buy

46.57%

Upside

Reiterated

08/03/26

Analysts Offer Insights on Healthcare Companies: Mettler-Toledo (NYSE: MTD), AnaptysBio (NASDAQ: ANAB) and Alnylam Pharma (NASDAQ: ALNY)

Unknown Analyst

Wells Fargo

Not Ranked

Wells Fargo

CHF304.88→CHF255.55

Hold

2.93%

Upside

Reiterated

07/31/26

Alnylam Pharma (ALNY) Receives a Hold from Wells Fargo

Ritu Baral

TD Cowen

CHF389.79

Buy

57.00%

Upside

Assigned

07/31/26

Analysts Conflicted on These Healthcare Names: Alnylam Pharma (NASDAQ: ALNY), Stryker (NYSE: SYK) and Bicycle Therapeutics (NASDAQ: BCYC)

Faisal Khurshid

Jefferies

CHF186

Hold

-25.09%

Downside

Reiterated

07/31/26

Jefferies Sticks to Their Hold Rating for Alnylam Pharma (ALNY)

Paul Matteis

Stifel Nicolaus

CHF359.06→CHF257.16

Buy

3.58%

Upside

Assigned

07/31/26

Alnylam price target lowered to $318 from $444 at StifelAlnylam price target lowered to $318 from $444 at Stifel

Martin Auster

Raymond James

CHF378.47→CHF339.65

Buy

36.80%

Upside

Reiterated

07/31/26

Alnylam price target lowered to $420 from $468 at Raymond JamesAlnylam price target lowered to $420 from $468 at Raymond James

Michael Ulz

Morgan Stanley

CHF323.48→CHF242.61

Hold

-2.28%

Downside

Reiterated

07/31/26

Alnylam Pharma (ALNY) Gets a Hold from Morgan Stanley

Kostas Biliouris

Oppenheimer

CHF404.34→CHF283.04

Buy

14.00%

Upside

Reiterated

07/31/26

Alnylam price target lowered to $350 from $500 at OppenheimerAlnylam price target lowered to $350 from $500 at Oppenheimer

Myles Minter

William Blair

―

Buy

―

Reiterated

07/30/26

Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (NASDAQ: BCYC), Alnylam Pharma (NASDAQ: ALNY) and Fortrea Holdings Inc. (NASDAQ: FTRE)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Cory Kasimov

Evercore ISI

CHF323.48→CHF262.82

Buy

5.86%

Upside

Reiterated

08/05/26

Alnylam price target lowered to $325 from $400 at Evercore ISIAlnylam price target lowered to $325 from $400 at Evercore ISI

Patrick Trucchio

H.C. Wainwright

CHF392.21→CHF367.95

Buy

48.20%

Upside

Reiterated

08/04/26

H.C. Wainwright Sticks to Its Buy Rating for Alnylam Pharma (ALNY)

Danielle Brill

Truist Financial

CHF331.56→CHF254.74

Buy

2.60%

Upside

Assigned

08/04/26

Truist Financial Releases a Buy Rating on Alnylam Pharma (ALNY)

Jessica Fye

J.P. Morgan

CHF303.26

Buy

22.14%

Upside

Reiterated

08/04/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (NASDAQ: ARWR), OnKure Therapeutics (NASDAQ: OKUR) and Alnylam Pharma (NASDAQ: ALNY)

Whitney Ijem

Canaccord Genuity

CHF346.93

Buy

39.73%

Upside

Reiterated

08/03/26

Canaccord Genuity Sticks to Their Buy Rating for Alnylam Pharma (ALNY)

Eric Joseph

Citi

CHF307.3→CHF274.95

Buy

10.74%

Upside

Reiterated

08/03/26

Alnylam price target lowered to $340 from $380 at CitiAlnylam price target lowered to $340 from $380 at Citi

Eliana Merle

Barclays

CHF426.18→CHF363.91

Buy

46.57%

Upside

Reiterated

08/03/26

Analysts Offer Insights on Healthcare Companies: Mettler-Toledo (NYSE: MTD), AnaptysBio (NASDAQ: ANAB) and Alnylam Pharma (NASDAQ: ALNY)

Unknown Analyst

Wells Fargo

Not Ranked

Wells Fargo

CHF304.88→CHF255.55

Hold

2.93%

Upside

Reiterated

07/31/26

Alnylam Pharma (ALNY) Receives a Hold from Wells Fargo

Ritu Baral

TD Cowen

CHF389.79

Buy

57.00%

Upside

Assigned

07/31/26

Analysts Conflicted on These Healthcare Names: Alnylam Pharma (NASDAQ: ALNY), Stryker (NYSE: SYK) and Bicycle Therapeutics (NASDAQ: BCYC)

Faisal Khurshid

Jefferies

CHF186

Hold

-25.09%

Downside

Reiterated

07/31/26

Jefferies Sticks to Their Hold Rating for Alnylam Pharma (ALNY)

Paul Matteis

Stifel Nicolaus

CHF359.06→CHF257.16

Buy

3.58%

Upside

Assigned

07/31/26

Alnylam price target lowered to $318 from $444 at StifelAlnylam price target lowered to $318 from $444 at Stifel

Martin Auster

Raymond James

CHF378.47→CHF339.65

Buy

36.80%

Upside

Reiterated

07/31/26

Alnylam price target lowered to $420 from $468 at Raymond JamesAlnylam price target lowered to $420 from $468 at Raymond James

Michael Ulz

Morgan Stanley

CHF323.48→CHF242.61

Hold

-2.28%

Downside

Reiterated

07/31/26

Alnylam Pharma (ALNY) Gets a Hold from Morgan Stanley

Kostas Biliouris

Oppenheimer

CHF404.34→CHF283.04

Buy

14.00%

Upside

Reiterated

07/31/26

Alnylam price target lowered to $350 from $500 at OppenheimerAlnylam price target lowered to $350 from $500 at Oppenheimer

Myles Minter

William Blair

―

Buy

―

Reiterated

07/30/26

Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (NASDAQ: BCYC), Alnylam Pharma (NASDAQ: ALNY) and Fortrea Holdings Inc. (NASDAQ: FTRE)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

AMLXAmylyx Pharmaceuticals Inc

TNYATenaya Therapeutics

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Alnylam Pharma

3 Months

Keay NakaeChardan Capital

Success Rate

25/40 ratings generated profit

Average Return

+5.67%

Copying Keay Nakae's trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +5.67% per trade.

1 Year

Paul MatteisStifel Nicolaus

Success Rate

22/32 ratings generated profit

Average Return

+14.91%

Copying Paul Matteis's trades and holding each position for 1 Year would result in 68.75% of your transactions generating a profit, with an average return of +14.91% per trade.

2 Years

Keay NakaeChardan Capital

Success Rate

28/40 ratings generated profit

Average Return

+34.44%

Copying Keay Nakae's trades and holding each position for 2 Years would result in 70.00% of your transactions generating a profit, with an average return of +34.44% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DUL Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DUL has received 47 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. DUL average Analyst price target in the past 3 months is 301.37.

Each month's total comprises the sum of three months' worth of ratings.

DUL Financial Forecast

DUL Earnings Forecast

Next quarter’s earnings estimate for DUL is CHF1.45 with a range of CHF1.04 to CHF2.40. The previous quarter’s EPS was CHF0.98. DUL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 42.68% of the time in the same period. In the last calendar year DUL has Performed in-line its overall industry.

DUL Sales Forecast

Next quarter’s sales forecast for DUL is CHF1.16B with a range of CHF1.11B to CHF1.21B. The previous quarter’s sales results were CHF1.04B. DUL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.58% of the time in the same period. In the last calendar year DUL has Performed in-line its overall industry.

DUL Stock Forecast FAQ

What is CH:DUL’s average 12-month price target, according to analysts?

Based on analyst ratings, Alnylam Pharmaceuticals’s 12-month average price target is 301.37.

What is CH:DUL’s upside potential, based on the analysts’ average price target?

Alnylam Pharmaceuticals has 21.38% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Alnylam Pharmaceuticals a Buy, Sell or Hold?

Alnylam Pharmaceuticals has a consensus rating of Strong Buy, which is based on 16 buy ratings, 3 hold ratings and 0 sell ratings.

What is Alnylam Pharmaceuticals’s share price target?

The average share price target for Alnylam Pharmaceuticals is 301.37. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF444.78 ,and the lowest forecast is CHF186.00. The average share price target represents 21.38% Increase from the current price of CHF248.28.

What do analysts say about Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of Alnylam Pharmaceuticals?

To buy shares of CH:DUL, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Alnylam Pharma (DUL) Stock Forecast & Price Target

DUL Analyst Ratings

DUL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Alnylam Pharma

DUL Analyst Recommendation Trends

DUL Financial Forecast

DUL Earnings Forecast

DUL Sales Forecast

DUL Stock Forecast FAQ

Detailed List of Analyst Forecasts